TITLE

Viral Vertigo

AUTHOR(S)
Langreth, Robert
PUB. DATE
November 2007
SOURCE
Forbes Asia;11/26/2007, Vol. 3 Issue 20, p102
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the effort of Vertex Pharmaceuticals to devise a new drug to combat hepatitis C. Vertex has a drug in the pipeline called telaprevir that it hopes will be the first in a new generation of hep C treatments. Telaprevir is a protease inhibitor that attacks the virus directly and blocks its replication. Vertex has already surmounted an array of problems since it started working on hepatitis C in 1993. Vertex executive John Thomson, says it became clear what a remarkable challenge designing a protease inhibitor would be.
ACCESSION #
27726602

 

Related Articles

  • Vertex: dipping into the non-responders pool.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p34 

    The article reports that Vertex Pharmaceuticals Inc. has unveiled encouraging results from a phase lb trial evaluating its vaccine, VX-950 in hepatitis C. Hepatitis C virus (HCV) protease inhibitors led by VX-950 are currently perceived as the most promising drug in the battle against chronic...

  • COMPANY SPOTLIGHT - Vertex Pharmaceuticals.  // PharmaWatch: Monthly Review;Jan2006, Vol. 5 Issue 1, p46 

    This article reports on the phase II clinical trial for VX-950, an investigational oral hepatitis C vaccine initiated by Vertex Pharmaceuticals Inc. The purpose of this trial is to study the treatment in combination with two existing therapies, pegylated interferon and ribavirin. Vertex is...

  • Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful.  // Biomedical Market Newsletter;5/21/2011, p755 

    The article reports that the phase 3 result in Telaprevir-Based Therapy study of Vertex Pharmaceuticals Inc. shows improvement in SVR (viral cure) rates in people with prior unsuccessful treatment for Hepatitis C in Berlin, Germany. JW Goethe University Hospital professor Stefan Zeuzem noted...

  • Vertex Hepatitis Drug WinsUS Panel Support.  // Clinical Infectious Diseases;7/15/2011, Vol. 53 Issue 2, preceding p107 

    The article reports that Vertex Pharmaceuticals Inc. has won an approval by an advisory panel of the U.S. for a new hepatitis C drug which almost increases the chances of curing the liver-destroying disease.

  • Hepatitis C: A "silent killer".  // Pharmacy Today;Aug2012, Vol. 18 Issue 8, p3 

    The article reports on the prevalence of hepatitis C in the U.S., wherein Vertex Pharmaceuticals Inc. has launched Better to Know C website, located at www.bettertoknowc.com, a website regarding the information on hepatitis C.

  • VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.  // Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p6 

    Reports on the agreement between Vertex Pharmaceuticals Inc. and Mitsubishi Pharma Corp. to develop and commercialize VX-950, Vertex's investigational oral protease inhibitor for the treatment of hepatitis C virus. Payments to be given by Mitsubishi to Vertex as part of the agreement; Statement...

  • Vertex Aims for $320M Offering to Push Telaprevir.  // Bioworld Week;2/23/2009, Vol. 17 Issue 8, p1 

    The article reports on the plan of Vertex Pharmaceuticals Inc. to sell its shares at around $32 for the development and commercialization of teleprevir for hepatitis C virus and VX-770. It states that the fund will help the firm through the anticipated 2011 launch of teleprevir. According to Ian...

  • Telaprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p179 

    Telaprevir (LY 570310; LY-570310; LY570310;MP 424;MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceuticals and its licensees for the treatment of HCV infections and has recently been...

  • Telaprevir Looks Ever-Better, But Don't Discount Boceprevir. Morrison, Trista // BioWorld Insight;8/16/2010, Vol. 18 Issue 33, p3 

    The article reports on the competition in the development of effective pharmacology for hepatitis C virus (HCV). Accordingly, Vertex Pharmaceuticals Inc. has reported a 75 percent HCV cure rate from the protease inhibitor telaprevir, while the boceprevir from Merck & Co. Inc. has reported a 66...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics